Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Mutual Pharmaceutical Company, Inc. |
---|---|
Information provided by: | Mutual Pharmaceutical Company, Inc. |
ClinicalTrials.gov Identifier: | NCT00785551 |
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or >50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy subjects versus those with mild to moderate renal impairment will be compared, as well.
Condition | Intervention | Phase |
---|---|---|
Healthy Renal Impairment |
Drug: quinine sulfate |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Parallel Assignment, Pharmacokinetics Study |
Official Title: | A Single-Dose, Open-Label Comparative Study of the Pharmacokinetics, Safety,and Tolerability of Oral Quinine Sulfate in Healthy Volunteers and Adults With Mild and Moderate Renal Impairment |
Estimated Enrollment: | 18 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
|
Drug: quinine sulfate
2 x 324mg given in one dose to healthy subjects
|
2: Experimental
quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
|
Drug: quinine sulfate
2 x 324mg given as one dose to subjects with mild renal impairment
|
3: Experimental
quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
|
Drug: quinine sulfate
2 x 324mg given as one dose to subjects with moderate renal impairment
|
Since many of the adverse events associated with quinine are dose-related, it is important to consider how varying degrees of renal dysfunction alter quinine pharmacokinetics possibly warranting dosage adjustment in these patients. This study will compare the pharmacokinetics of quinine in patients with normal, mild or moderate renal impairment. Eighteen non-smoking males and female volunteers between 18-65 years of age weighing at least 60 kg with BMI between 18- 40 kg/m2 will be divided into 3 groups of 6 subjects each based on renal function as defined (6 normal, 6 mild impairment, 6 moderate impairment). Subjects will be confined to the study unit during the entire 5 day study period beginning on the evening of Day -3. To confirm renal function classification, creatinine clearance will be measured via 24-hour urine collection from 7am Day -2 until 7am Day -1. On day 1, after a fast of at least 8 hours, each patient will receive a single 648 mg dose of quinine sulfate. Blood and urine samples will be collected at times sufficient to adequately define the pharmacokinetics of quinine and its active metabolite, 3'-hydroxyquinine) in the three study groups. Subjects will be monitored regarding adverse effects throughout study participation.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Allied Research International - Cetero Research | Recruiting |
Miami Gardens, Florida, United States, 33169 | |
Contact: Gil Weiner, MD 305-624-9191 | |
Principal Investigator: Gil Weiner, MD |
Study Chair: | Matthew Davis, M.D. | Mutual Pharmaceutical |
Responsible Party: | Mutual Pharmaceutrical Company ( Vice President Branded Products and Medical Affairs ) |
Study ID Numbers: | MPC-001-07-1008 |
Study First Received: | November 3, 2008 |
Last Updated: | November 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00785551 |
Health Authority: | United States: Food and Drug Administration |
male female pharmacokinetics normal and impaired renal function |
Quinine Healthy |
Anti-Infective Agents Antiprotozoal Agents Physiological Effects of Drugs Neuromuscular Agents Pharmacologic Actions Antimalarials Antiparasitic Agents |
Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Muscle Relaxants, Central Peripheral Nervous System Agents Analgesics Central Nervous System Agents |